- Home
- CCCC vs MEVO Comparison
CCCC vs MEVO Comparison
Compare CCCC & MEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCCC | MEVO |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 397.2M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CCCC | MEVO |
|---|---|---|
| Price | $3.70 | $9.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 45.5K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.69 | $9.83 |
| 52 Week High | $5.17 | $9.95 |
Technical Indicators
Market Signals| Indicator | CCCC | MEVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 70.85 |
| Support Level | $2.10 | $9.83 |
| Resistance Level | $3.89 | N/A |
| Average True Range (ATR) | 0.37 | 0.01 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 16.47 | 100.00 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
About MEVO M Evo Global Acquisition Corp II Class A Ordinary Shares
M Evo Global Acquisition Corp II is a blank check special purposr acquisition company.